House Committee Probes Merck (MRK), AbbVie China Trials

Merck & Co. (NYSE:MRK), the pharmaceutical giant behind blockbuster drugs like Keytruda and Gardasil, is facing fresh scrutiny after a bipartisan group of lawmakers opened a national security inquiry into the company's clinical trial operations in China. The news lands as MRK shares trade at 128.5 dollars, down 0.68% on the day, with the stock sitting near the top of its 52 week range.

At a Glance

• Price: 128.5 USD, down 0.68% on the day
• 52 week range: 107.9 to 130.29
• Market cap: 317.77 billion dollars
• P/E ratio: 35.99, EPS implied by earnings
• Dividend yield: 2.65%, RSI at 68.01

What the Congressional Inquiry Actually Alleges

Representative John Moolenaar of Michigan, who chairs the House Select Committee on the Chinese Communist Party, sent letters dated Monday to Merck CEO Robert Davis and AbbVie CEO Robert Michael. The letters, first reported by Reuters, request that both companies detail their due diligence practices, data protection standards and oversight procedures for clinical trial sites operating in China, with particular attention to Xinjiang and to sites located at military hospitals. The committee has given both firms until July 17 to respond.

The letters specifically flag Xinjiang as the site of what lawmakers describe as genocide against Uyghurs and other ethnic and religious minorities, and they cite documented lapses by Chinese researchers in obtaining informed consent from trial participants. Lawmakers point to the Uyghur Forced Labor Prevention Act of 2021 as a benchmark for ethical operating standards, even though that law does not directly govern clinical trial conduct. Notably, the letters state plainly that there is no evidence either company has engaged in illegal activity or wrongdoing. The concern raised is one of exposure, not proven misconduct.

Merck responded that patient safety and ethical integrity remain central to its clinical research program and said it adheres to global regulatory guidelines. AbbVie declined to comment. A spokesperson for China's embassy in Washington dismissed the committee's actions as lacking credibility and accused U.S. lawmakers of politicizing trade and technology issues.

Why China Has Become a Trial Hub

The inquiry taps into a broader structural shift in where drug development actually happens. Lawmakers' letters describe China as having become, through regulatory reform, state subsidies and what they call questionable ethical oversight, the cheapest and fastest place in the world to run early stage human drug trials. The numbers back up the scale of that shift: the U.S. share of global early stage drug development programs fell from roughly 48% in 2015 to about 37% by 2024, while China's share climbed from 8% to more than 32% over the same period, according to industry data cited in the letters.

That migration has not gone unnoticed inside Washington's national security establishment. A December report from the National Security Commission on Emerging Biotechnology warned that China has built a vertically integrated biotechnology ecosystem now positioned to challenge U.S. leadership in the sector. The Merck and AbbVie letters fit into that pattern of growing congressional concern over how deeply American pharmaceutical companies have embedded their research and development pipelines in Chinese infrastructure, including sites tied to the military.

What the Numbers Say

Merck's valuation multiple sits at a P/E of 35.99, elevated relative to the broader pharmaceutical sector and reflective of investor expectations that the company's pipeline, led by Keytruda, continues to justify a premium despite looming patent exposure later this decade. At 128.5 dollars, the stock trades just below its 52 week high of 130.29 and well above its low of 107.9, a range that shows a stock that has recovered strongly over the past year.

Momentum readings tell a more cautious story. An RSI of 68.01 places Merck close to the conventional overbought threshold of 70, suggesting the recent rally has been forceful enough that further upside could face resistance without a corresponding pullback or consolidation. Income focused holders, meanwhile, continue to collect a 2.65% dividend yield, a level that remains attractive relative to Treasury yields for investors prioritizing steady income alongside capital appreciation.

The bull case rests on Merck's diversified oncology and vaccine franchises, continued Keytruda demand, and a balance sheet capable of absorbing regulatory noise without altering near term guidance. The bear case centers on headline risk: a formal congressional investigation into trial practices in a geopolitically sensitive region could invite further regulatory attention, complicate future trial site selection, or feed into broader U.S. China biotech decoupling narratives that pressure multiples across the sector, even absent any finding of wrongdoing.

Frequently Asked Questions

What exactly are lawmakers investigating at Merck?

The House Select Committee on the Chinese Communist Party is examining Merck's due diligence, data protection processes and ethical standards at clinical trial sites in China, particularly in Xinjiang and at military hospitals. The committee has asked for detailed responses by July 17.

Has Merck been accused of wrongdoing?

No. The lawmakers' letters explicitly state there is no evidence that Merck or AbbVie engaged in illegal activity or wrongdoing. The inquiry focuses on the ethical and security risks inherent in conducting trials in China rather than on any specific violation.

How has Merck stock performed relative to its 52 week range?

Merck shares at 128.5 dollars are trading near the top of their 52 week range of 107.9 to 130.29, reflecting a strong recovery over the past year despite the 0.68% decline recorded on the day the investigation became public.

Why has China become such a large hub for clinical trials?

Industry data shows China's share of global early stage drug development rose from 8% in 2015 to over 32% by 2024, driven by regulatory reforms, state subsidies and lower operating costs, while the U.S. share fell from 48% to roughly 37% over the same period.

What Comes Next for Merck

The July 17 deadline gives Merck and AbbVie roughly two and a half weeks to compile detailed responses on trial oversight practices that stretch back years. How thoroughly they document informed consent procedures and data security protocols at Chinese sites will likely determine whether this inquiry escalates into formal hearings or fades after an initial exchange of information. For now, the stock's technical posture, elevated RSI paired with a valuation near multi year highs, suggests the market has yet to price in any meaningful disruption from the congressional letters.